A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Active Ankylosing Spondylitis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Active Ankylosing Spondylitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms POSTURE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 11 Jan 2016 According to a Celgene Corporation media release, long-term radiographic data from this trial is expected in 2016.
    • 26 Aug 2015 Planned End Date changed from 1 Dec 2018 to 1 Oct 2018, as reported by ClinicalTrials.gov record.
    • 22 Jul 2014 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top